Betty Wang, MD, and Laura Bukavina, MD, MPH, MSc, discuss ctDNA's role in NMIBC treatment decisions
Wang and Bukavina outline several cases of ctDNA's utility in the space.
Andrea Pezzella, MD, URPS, FACOG, discusses Neuspera's integrated sacral neuromodulation system
Pezzella said she believes Neuspera offers a "smart, integrated, sophisticated alternative" for treating overactive bladder symptoms.
Mina Fam, MD, on managing expectations around testosterone replacement therapy
Mina M. Fam, MD, discusses some of the common misconceptions that patients have when seeking testosterone replacement therapy.
Justin Dubin, MD, on the role for AI in patient education
“With the right use, AI can and hopefully will play a massive role in patient education,” says Justin M. Dubin, MD.
Considerations for pre-procedure urinalysis, periprocedural antibiotics for onabotA
Benjamin M. Brucker, MD, outlines considerations surrounding pre-procedure urinalysis, prophylactic periprocedural antibiotics, and optimal dosing regimens for onabotA administration.
TMT for bladder cancer: Balancing cost and quality of life
According to Daniel D. Joyce, MD, MS, policy initiatives should focus on improving the value and efficiency of radiation.
Anne Schuckman, MD, outlines current challenges in NMIBC care
Anne K. Schuckman, MD, discusses some of the current challenges in delivering optimal care for patients with non–muscle invasive bladder cancer.
Justin Dubin, MD, on the use of AI in the male infertility space
Justin M. Dubin, MD, outlines the current ways that artificial intelligence is being used in the male infertility space.
Bilal Chughtai, MD, discusses pivotal trial of the Butterfly device for BPH
Bilal I. Chughtai, MD, walks through the design and potential implications of a pivotal trial of the Butterfly Prostatic Device.
Investigators compare trimodal therapy vs cystectomy in MIBC
Findings indicated that although trimodal therapy improved the quality of life for patients with muscle-invasive bladder cancer compared with cystectomy, its significantly higher cost made it not cost-effective.
Investigators assess ctDNA’s role in NMIBC
A notable finding was that 35% of these NMIBC patients exhibited ctDNA positivity.
Vignesh Packiam, MD, on the MOA, dosing of detalimogene voraplasmid
Vignesh T. Packiam, MD, outlines the mechanism of action for detalimogene voraplasmid as well as its potential benefits in terms of storage and dosing.
Understanding pediatric urologist burnout
The most apparent risk factor is hours worked, as increased work hours directly correlate with heightened tiredness and stress.
Urologist finds Rezum AE rates in larger prostates “reassuring”
McVary's expectation is that the results will be sustainable because the short-term outcomes for larger prostates appear superimposable on the longer-term outcomes for smaller, previously restricted prostate volumes
Men’s Health Awareness Month: A new era of patient engagement
Justin Dubin, MD, touches on the current landscape of men’s health, with a specific focus on the advent of AI.
Laura Davis, MD, on persistent poverty and early onset prostate cancer
Laura E. Davis, MD, discusses the link between early onset prostate cancer and persistent poverty.
Nicolette G. Payne, MD, discusses the rise in burnout among pediatric urologists
One prominent theory suggests that younger generations of graduating urologists face increased financial pressures due to higher student loan debt.
Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
The ARASTEP trial is exploring the combination of darolutamide plus ADT vs ADT alone in patients with high-risk biochemical recurrence of prostate cancer.
Kevin T. McVary, MD, FACS, discusses the expanded label for Rezum in BPH
The system is now cleared for use in prostates up to 150 cm3.
Amy Krambeck, MD, on considerations for building clinical programs in endourology
Amy E. Krambeck, MD, discusses how to define success and how to determine the optimal timing for adding on a new partner.
Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
Olivares cautioned that HIFU is not suitable for all patients, particularly those with more aggressive disease, for whom complete gland removal may still be necessary.
Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
“The takeaway is that on a population level, on a health care system perspective, it's more cost-effective and safer to do transperineal prostate biopsy,” says Mitchell M. Huang, MD.
David Stanley, MD, on current trends in the management of kidney stones
David Stanley, MD, FACS, discusses current trends and unmet needs in the treatment of patients with kidney stones.
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Alicia K. Morgans, MD, MPH, highlights quality of life data from the phase 3 ARANOTE trial.
Post-RP incontinence: Low procedure rates examined
The findings strongly support a proactive approach to identifying and referring patients with poor urinary function after RP.
Roger Dmochowski, MD, on quality-of-life outcomes with the Revi System
Treatment with the Revi System led to durable QOL benefits at 24 months, even among those patients who did not achieve the primary end point.
Anne Schuckman, MD, highlights promising new developments in NMIBC
Anne Schuckman, MD, on optimal sequencing strategies, the SWOG 1602 trial, and the emerging role of ctDNA.
Amir Patel, MD, on onabotulinumtoxinA injection at the time of HoLEP
Amir S. Patel, MD, discusses interim findings from a randomized controlled trial of onabotulinumtoxinA injection at the time of HoLEP vs standard treatment.
Data link incontinence severity to post-radical prostatectomy care
The investigators found a clear, dose-response relationship between patient-reported incontinence severity and the subsequent use of incontinence interventions such as artificial sphincters or bulking agents.
Margaret Knoedler, MD, on robot-assisted mini-PCNL with the MONARCH Platform
Margaret A. Knoedler, MD, discusses the advantages of using the MONARCH platform for mini-PCNL.
